Clinical Influence of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors for Cardiovascular and Renal Points of View
Open Access
- 30 January 2020
- journal article
- Published by Asploro Open Access Publications
- Vol. 2 (S1), 9-13
- https://doi.org/10.36502/2020/droa.6156
Abstract
Diabetes has been a major medical and health problem worldwide. Adequate glycemic control has shown a clinically beneficial effect for long-term prognosis, with recent anti-diabetic agents. There are some mega studies concerning Sodium-glucose cotransporter 2 (SGLT2) inhibitors. They are i) Canagliflozin cardioVascular Assessment Study (CANVAS), ii) Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), iii) Dapagliflozin Effect on CardiovascuLAR Events (DECLARE) -TIMI 58, iv) Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) study. Current topics of SGLT2 inhibitors for cardiovascular and renal points of view were described.Keywords
This publication has 20 references indexed in Scilit:
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyThe New England Journal of Medicine, 2019
- Difference of Glucose variability between Low Carbohydrate Diet (LCD) and Calorie Restriction (CR)Asploro Journal of Biomedical and Clinical Case Reports, 2019
- Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of PhysiciansAnnals of Internal Medicine, 2018
- Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular OutcomesDiabetes Care, 2016
- Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 DiabetesThe New England Journal of Medicine, 2015
- Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 DiabetesThe New England Journal of Medicine, 2014
- Glucose Control and Vascular Complications in Veterans with Type 2 DiabetesThe New England Journal of Medicine, 2009
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesThe New England Journal of Medicine, 2008
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998